COMMUNIQUÉS West-GlobeNewswire

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
20/04/2026
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living [...]
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
20/04/2026
STAFFORD, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
20/04/2026
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026 A non-invasive topical [...]
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
20/04/2026
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectivity and reduced off- [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
20/04/2026
President Trump signed an Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS on April 18, 2026. The order directs acceleration of research and lowered barriers to approvals of psychedelic [...]
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
20/04/2026
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the pricing of its [...]
Soleo Health Expands Rare Disease Capabilities With Launch of SoleoRare™, A Specialty Pharmacy Focused on Complex Patient Needs
20/04/2026
New brand reflects years of expertise and a deepened commitment to the rare disease community FRISCO, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Soleo Health , an innovative leader and national provider of complex [...]
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
20/04/2026
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is the generic [...]
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
20/04/2026
Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026 A non-invasive topical treatment for diabetic macular edema (DME) has the [...]
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
20/04/2026
SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage [...]
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
20/04/2026
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer Prelude Remains on Track to File [...]
KFSH Joins C3 Davos of Healthcare™ 2026 in Sunnyvale, California, as a Global Strategic Partner
20/04/2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will participate as a Global Strategic Partner at the C3 Davos of Healthcare™ Silicon Valley Summit, [...]
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
20/04/2026
SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
20/04/2026
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live biotherapeutics in [...]
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
20/04/2026
Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care 1 Haemoglobin response was superior with etavopivat: 48.7% of people [...]
Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
20/04/2026
Press Release Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026 April 20, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an [...]
Nanobiotix annonce de nouvelles données précliniques démontrant une amélioration de la biodisponibilité systémique et la réduction de la toxicité pour des immunothérapies à ADN delivrées par LNP après traitement avec sa technologie de nanoprimer
20/04/2026
Une étude préclinique chez la souris a évalué le potentiel de la technologie nanoprimer à surmonter les barrières courantes rencontrées par les thérapies délivrées par nanoparticules lipidiques (« LNP »), qui sont [...]
Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026
20/04/2026
Communiqué de presse Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026 20 avril 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA ( [...]
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
20/04/2026
This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipeline Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, [...]

Pages